Monoclonal Antibody-Based Therapy for Eosinophilic Oesophagitis

Abstract

Eosinophilic oesophagitis is an inflammatory condition associated with marked eosinophil accumulation in the mucosal tissues of the oesophagus. Eosinophils are major pro-inflammatory cells thought to make a significant contribution to allergic diseases that affect the upper and lower airways, skin, and gastrointestinal tract. Type 2 cytokines such as interleukin (IL)-5 and IL-13 are central to eosinophil maturation and release from the bone marrow, and their subsequent accumulation, activation, and persistence in the tissues. Humanised monoclonal antibodies with potent IL-5 or IL-13 neutralising effects represent potential treatments for eosinophilic-driven diseases. This review will consider the current status of these biologics in the treatment of eosinophilic esophagitis.

Biologicals for the prevention of anaphylaxis

“…Reslizumab is authorized for adults with a blood eosinophilic count 400 cells/ mL. It is also being studied for eosinophilic esophagitis and nasal polyposis [13][14][15][16][17]18 ]. Anti-IL4/13 (Dupilumab) was initially approved for patients aged 12 years and above with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.…”